دورية أكاديمية
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes
| العنوان: | Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes |
|---|---|
| المؤلفون: | Engelen, Lian, Lund, Soren S., Ferreira, Isabel, Tarnow, Lise, Parving, Hans-Henrik, Gram, Jorgen, Winther, Kaj, Pedersen, Oluf, Teerlink, Tom, Barto, Rob, Stehouwer, Coen D. A., Vaag, Allan, Schalkwijk, Casper G. |
| المصدر: | European Journal of Endocrinology; 164(3), pp 371-379 (2011) ; ISSN: 1479-683X |
| بيانات النشر: | Society of the European Journal of Endocrinology |
| سنة النشر: | 2011 |
| المجموعة: | Lund University Publications (LUP) |
| مصطلحات موضوعية: | Endocrinology and Diabetes |
| الوصف: | Objective: Metformin has been reported to reduce alpha-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of alpha-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the alpha-dicarbonyl 3-deoxyglucosone (3DG). Methods: We conducted a single-center, double-masked, double-dummy, crossover study involving 96 nonobese patients with type 2 diabetes. After a 1-month run-in on diet-only treatment, patients were randomized to either repaglinide (6 mg daily) followed by metformin (2 g daily) or vice versa each during 4 months with a 1-month washout between interventions. Results: 3DG levels decreased after both metformin (-19.3% (95% confidence interval (CI): -23.5, -14.8)) and repaglinide (-20.8% (95% CI: -24.9, -16.3)) treatments, but no difference was found between treatments (1.8% (95% CI: -3.8, 7.8)). Regardless of the treatment, changes in glycemic variables were associated with changes in 3DG. Specifically, 3DG decreased by 22.7% (95% CI: 19.0, 26.5) per S. D. decrease in fasting plasma glucose (PG), by 20.0% (95% CI: 16.2, 23.9) per S. D. decrease in seven-point mean plasma glucose, by 22.5% (95% CI: 18.6, 26.6) per S. D. decrease in area under the curve for PG, by 17.2% (95% CI: 13.8, 20.6) per S. D. decrease in HbAlc, and by 10.9% (95% CI: 6.4, 15.5) per S. D. decrease in Amadori albumin. In addition, decreases in 3DG were associated with decreases in advanced glycation endproducts and endothelial markers. Conclusion: Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in 3DG levels in nonobese individuals with type 2 diabetes. This may constitute a shared metabolic pathway through which both treatments have a beneficial impact on the cardiovascular risk. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://lup.lub.lu.se/record/1869787Test; http://dx.doi.org/10.1530/EJE-10-0851Test; wos:000287969100008; scopus:79951971683; pmid:21205874 |
| DOI: | 10.1530/EJE-10-0851 |
| الإتاحة: | https://doi.org/10.1530/EJE-10-0851Test https://lup.lub.lu.se/record/1869787Test |
| رقم الانضمام: | edsbas.9A9FB110 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1530/EJE-10-0851 |
|---|